Trump Administration Rule Forces Pharmacy Benefit Managers to Disclose Secret Drug Payment Data

A new federal rule from the Trump administration will compel pharmacy benefit managers (PBMs) to disclose fees and compensation details that have long been kept private. The rule targets the middlemen who negotiate drug prices between manufacturers, insurers, and pharmacies, aiming to bring transparency to a system that critics say inflates costs for patients and employers. PBMs have faced scrutiny for retaining rebates and charging spread pricing, often without clear disclosure to plan sponsors or regulators. By requiring these entities to share payment data, the administration seeks to expose hidden revenue streams and give employers and government programs better leverage in negotiations. The move could reshape how drug pricing is reported and audited, potentially leading to lower out-of-pocket costs for consumers. While the rule is expected to face legal challenges from industry groups, its implementation marks a significant shift in federal oversight of pharmaceutical supply chain economics. The requirement may also pressure PBMs to alter their business practices even before enforcement begins, as public disclosure invites comparison and accountability.